Target Conditions

iVeena is targeting the following ophthalmic disease states and has developed solutions to mitigate these diseases:

Post Surgery Cataract Inflammation (IVMED-10 and IVMED-20)

We are all born with a lens inside each eye, which becomes cloudy with time if one lives long enough. The cloudy lens is called a cataract, and without therapy, can cause all vision to become fuzzy. Vision can be restored by surgery to remove cataracts, which is the most common surgery in the US. In 2014, almost 4 million cataract surgeries were done in America and over 20 million worldwide. After surgery, patients typically have to take 3 different drops at 3 different schedules for 3 different periods of time to help the eye heal and protect it from complications. This is difficult and patients often do not take their medications as prescribed, leading to complications even if the surgery went perfectly. iVeena’s lead product, IVMED-10, is intended to facilitate the introduction of drop-free cataract surgery. IVMED-20 treats patients with high risk for Retinal Swelling.

Glaucoma (IVMED-70)

High pressure in the eye can damage the optic nerve and slowly lead to progressive loss of peripheral and then central vision. This is glaucoma, the second leading cause of blindness in the US (affecting 3 million Americans) and in the world (afflicting 70 million patients globally). Patients often have to take various eyedrops at various schedules indefinitely, again with substantial non-adherence. iVeena is developing a device, IVMED-70, to reduce intraocular pressure with an easy-to-perform surgery with low risk.

Keratoconus (IVMED-80) Orphan Drug Candidate:

First eye-drop, non-surgical, non-laser treatment for medical crosslinking for keratoconus. Degenerative disorder causing cornea to become conical in shape. The condition may lead to corneal transplant. Estimated prevalence < 50/100,000 (~160,000 in US qualifying as orphan disease). Opportunities in other indications (e.g., reduce risk of ectasia after LASIK)

Neurotrophic Keratopathy (IVMED-90) Orphan Drug Candidate:

Neurotrophic Keratopathy is a degenerative disease characterized by decreased corneal sensitivity and poor corneal healing. Progression of the disease can lead to the need for cornea transplant. NK is an orphan disease (approximately 160,000 cases annually in the US). The iVeena treatment is a topical drop that promotes corneal nerve growth.

Macular Degeneration (IVMED-50 / 55)

Death of cells in the central part of the retina (macula) together with bleeding or tissue swelling is known as age-related macular degeneration (AMD), the leading cause of blindness in the US, affecting 1.7 million Americans. The only treatment for this at present is monthly injections of anti-VEGF drugs; as can easily be imagined, injections to the eye can be painful and pose risks of infection, retinal detachment, and hemorrhage. iVeena is working on a long-term noninfectious gene therapy approach to restore the normal vascular barriers and preserve retinal cells. IVMED-50 would be administered by systemic injection. IVMED-55 would be a once-yearly inter ocular injection.

Diabetic Retinopathy (IVMED-60)

Diabetes can cause swelling, bleeding, and scarring of the retina. Diabetic retinopathy is the leading cause of blindness in the working-age population, affecting 7.7 million Americans. Current therapy for diabetic retinopathy is focused on fighting VEGF production, but does not address the loss of retinal blood vessels or lack of oxygen to the retina. iVeena’s innovative gene therapy will preserve retinal blood vessels in the face of diabetes, restore normal oxygenation to the retina, and hopefully prevent and treat DME and PDR. This product would be administered by intravenous injection.